Company Introduction

Sinoway was set up in 1987 and it is state-owned enterprise.

Our Main Service
※ Custom Developing & Manufacturing for APIs / key Intermediates (e.g. polypeptide derivatives, prostaglandin derivatives etc.) / Finish Dosage form.
※ Import & Export for APIs/ Intermediates / Finish dosage form / Food supplement / Cosmetic raw material
※ Technology Transfer for Finish Dosage Form.

Our Hot Items

i"Me-too" new drugs development; API advanced intermediates (Avoid current patent) , e.g. Febuxostat, Silodosin, Rosuvastatin key intermediates etc.

ii Polypeptide derivatives, e.g. Octreotide, Glatiramer, Liraglutide etc.

iii Prostaglandin Derivatives, e.g. Cloprostenol Key intermediates etc.

iv Multi-step synthesis, e.g. chiral compound (more than 15 steps) and Scale-up in KG and Process Optimization.

v PEG Chemistry: PEGylation drugs (4-Arm-PEG-Gyl-Irinotecan and PEG-Naloxone), PEG conjugates and proteins for long term controlled released drugs.

vi Drug delivery system: Block copolymers and "proof-of-concept" for use

Products under the patent are only for R&D use.

ADD: Huicheng Comm. Complex. No.839 Xiahe Rd, Xiamen, China;
Tel: +86-592-5853819; Website: www.sinowaychem.com
Sinoway Industrial Co., Ltd.

ISO 9001:2008

Custom Developing/Custom Manufacturing
For API&Intermediates

**EVALUATION**
- evaluate the possibility
  1 week – 2 weeks

**PILOT SCALE**
- evaluate the cost
  and quality
  3 months

**LAB SCALE**
- evaluate the quality
- make sample
  1 month

**COMMERCIAL PRODUCTION**
  6 months

**We can do...**
We are professional of these compounds
1. Chiral compounds
2. Carbohydrate chemistry
3. Peptide synthesis
4. Create a new synthetic route which is different from patent route (avoid patent)
   For example, we have successfully developed Rosuvastatin T-Butylaminesalt etc.

We are specialized in these reactions
1. Grignard reagent
2. Oxidation / Reduction
3. Ring closure reaction
4. Condensation reaction
5. Halogenation
6. Nitration
7. Amination

We have special facilities that can meet these circumstances
1. High vacuum (reach 1mmHg)
2. Low temperature (reach -100°C)
3. Enzymic catalytic reaction

ADD: Huicheng Comm.Complex.No.839 Xiahe Rd, Xiamen,China;
Tel:+86-592-5853819;Website:www.sinowaychem.com
APIs

Atracurium Besylate  USP38 or EP8
Budesonide  EP8
Diosmin/Hesperidin 90:10 refer to EP8
Dasatinib hydrate  99% up by HPLC
Esomeprazole Magnesium  EP8.2/USP38
Ezetimibe  99% by HPLC
Fentanyl Citrate USP37 or EP7 (subject to CFDA’s export license)
Hydrocortisone Acetate  EP8/USP39
Losartan Potassium  EP8/USP39
Lenalidomide  98.0%~102.0%
LCZ696  Assay of Valsartan 48.9~52.4%
         Assay of Sacubitril 49.8%~52.4%
Mupirocin  USP37
Nifuratel  99.9% up by HPLC
Orlistat  USP38
Olmesartan medoxomil  EP8
Pregabalin  99% up by HPLC
Rosuvastatin Calcium  EP8
Spironolactone  EP8

All goods are produced in GMP certified workshop
Products under the patent are only for R&D use.

ADD: Huicheng Comm. Complex No.839 Xiahe Rd, Xiamen, China
Tel:+86-592-5853819; Website: www.sinowaychem.com
<table>
<thead>
<tr>
<th>Product Name</th>
<th>Purity by HPLC</th>
<th>CAS Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aripiprazole Intermediates</td>
<td>99% up by HPLC</td>
<td>CAS: 119532-26-2, CAS: 129722-34-5 etc.</td>
</tr>
<tr>
<td>Bortezomib intermediates</td>
<td>99% up by HPLC</td>
<td>CAS: 179324-87-9 etc.</td>
</tr>
<tr>
<td>Dabigatran Intermediate</td>
<td>99% up by HPLC</td>
<td>CAS: 211914-50-0</td>
</tr>
<tr>
<td>Entecavir intermediate</td>
<td>99% up by HPLC</td>
<td>CAS: 1354715-15-3 etc</td>
</tr>
<tr>
<td>Febuxostat intermediate</td>
<td>99% up by HPLC</td>
<td>CAS: 160844-75-7, CAS: 161798-03-4</td>
</tr>
<tr>
<td>Minodronic Acid intermediate</td>
<td>99% up by HPLC</td>
<td>CAS: 2930-66-9 etc.</td>
</tr>
<tr>
<td>Rosuvastatin calcium</td>
<td>99% up by HPLC</td>
<td>CAS: 147118-40-9; CAS: 147118-35-2 etc.</td>
</tr>
<tr>
<td>intermediates</td>
<td>S. Impurity &lt; 0.1%</td>
<td></td>
</tr>
<tr>
<td>Pitavastatin calcium</td>
<td>99.5% up by HPLC</td>
<td>CAS: 147511-70-4; CAS: 147489-06-3 etc.</td>
</tr>
<tr>
<td>intermediates</td>
<td>S. Impurity &lt; 0.1%</td>
<td></td>
</tr>
<tr>
<td>Rabeprazole Sodium intermediates</td>
<td>99% up by HPLC</td>
<td>CAS: 675198-19-3; CAS: 117977-21-6 etc.</td>
</tr>
<tr>
<td>Rivaroxaban intermediates</td>
<td>99% up by HPLC</td>
<td>CAS: 446292-07-5 etc.</td>
</tr>
<tr>
<td>Solifenacin succinate</td>
<td>99% up by HPLC</td>
<td>CAS: 118864-75-8 etc.</td>
</tr>
<tr>
<td>intermediates</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vildagliptin intermediates</td>
<td>99% up by HPLC</td>
<td>CAS: 702-82-9 etc.</td>
</tr>
<tr>
<td>M-Nitrobenzaldehyde/</td>
<td>99% up by HPLC</td>
<td>CAS: 99-61-6; CAS: 552-89-6</td>
</tr>
<tr>
<td>O-Nitrobenzaldehyde</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-Hydroxybenzyl alcohol</td>
<td>99% up by HPLC</td>
<td>CAS: 623-05-2</td>
</tr>
</tbody>
</table>

**Products under the patent are only for R&D use.**

ADD: Huicheng Comm.Complex.No.839 Xiahe Rd, Xiamen,China;
Tel:+86-592-5853819;Website:www.sinowaychem.com
<table>
<thead>
<tr>
<th>Food Supplement / Plant Extract</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aloe Vera Extract</td>
</tr>
<tr>
<td>Beta-Carotene</td>
</tr>
<tr>
<td>Bilberry Extract</td>
</tr>
<tr>
<td>Citicoline</td>
</tr>
<tr>
<td>Coenzyme Q10</td>
</tr>
<tr>
<td>Giant Knotweed Extract</td>
</tr>
<tr>
<td>Ginkgo Biloba Extract</td>
</tr>
<tr>
<td>Green Tea Extract</td>
</tr>
<tr>
<td>Griffonia Seed Extract</td>
</tr>
<tr>
<td>L-Carnosine</td>
</tr>
<tr>
<td>Lycopene</td>
</tr>
<tr>
<td>Marigold Extract</td>
</tr>
<tr>
<td>Natural Creosote</td>
</tr>
<tr>
<td>Olive Leaf Extract</td>
</tr>
<tr>
<td>Phosphatidyl Serine</td>
</tr>
<tr>
<td>S-Adenosyl-L-methionine Disulfate Tosylate</td>
</tr>
<tr>
<td>Stevia Extract</td>
</tr>
<tr>
<td>Soybean Extract</td>
</tr>
<tr>
<td>Saw Palmetto Extract</td>
</tr>
</tbody>
</table>
Cosmetic Raw materials

Cosmetic peptides

Argireline (Acetyl Hexapeptide-3)  98% up  
Copper peptide (GHK-CU or AHK-Cu)  98% up  
Matrixyl 3000 (Pal-GHK:Pal-GQPR=2:1)  95% up  
Nonapeptide-1  95% up  
Matrixyl(Palmitoyl Pentapeptide-4)  98% up  
SNAP-8 (Acetyl Octapeptide-8 )  98% up  
Syn-Coll (Palmitoyl Tripeptide-5)95% up

* Custom Developing /Manufacturing for Polypeptides Derivatives

Others

Azelaic acid  99.5% up by HPLC  
Alpha/Beta Arbutin  99.5%  
L-Cysteine Base  AJI92  
Fish Collagen  97%  
Guaiazulene  99.9% up by HPLC  
L-Glutathione reduced  USP37 / EP7  
Sodium Hyaluronate  95% up  
S-Acetyl-L-Glutathione  98% up

Products under the patent are only for R&D use.

ADD: Huicheng Comm.Complex.No.839 Xiahe Rd, Xiamen,China;  
Tel:+86-592-5853819;Website:www.sinowaychem.com
Prostaglandin(P.G) Series

I. Key intermediates

(-)-Corey lactone p-phenylbenzoate alcohol  Cas: 31752-99-5  98%~102%

(-)-Corey Lactone Diol  Cas: 32233-40-2  99%

(-)-Corey Lactone Benzoate  Cas: 39746-00-4  99%

II. Prostaglandin Derivatives

Alprostadil  USP32/EP7

Bimatoprost  99.5%

DL /D-Cloprostenol Sodium  99% up

Dinoprost tromethamine  99%

Limaprost  99%

Latanoprost  99%

Lubiprostone  99%

Misoprostol  99%

Travoprost  USP34

Treprostinil Sodium  99%

*Custom Developing /Manufacturing for Polypeptides Derivatives
ADD: Huicheng Comm.Complex.No.839 Xiahe Rd, Xiamen,China;
Tel:+86-592-5853819;Website:www.sinowaychem.com
Finish Dosage form

1. We are looking for long-term partners to import & transfer advanced technology of FDF to China.

2. We export FDF with special know-how and production advantage from China

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Strength</th>
<th>RA Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rabeprazole Sodium Enteric-coated Capsules</td>
<td>10mg</td>
<td>CFDA</td>
</tr>
<tr>
<td>Clindamycin HCL capsules</td>
<td>75mg;150mg;300mg</td>
<td>EU GMP</td>
</tr>
<tr>
<td>Doxycycline HCL capsule</td>
<td>100mg</td>
<td>US FDA</td>
</tr>
<tr>
<td>Letrozole Tablets</td>
<td>2.5mg</td>
<td>US FDA, EU GMP, Japanese PMDA</td>
</tr>
<tr>
<td>Acarbose tablets</td>
<td>50mg;100mg</td>
<td>EU GMP</td>
</tr>
<tr>
<td>Montelukast Sodium Chewable Tablets</td>
<td>4mg;5mg;10mg</td>
<td>US FDA</td>
</tr>
<tr>
<td>Capecitabine Tablets</td>
<td>150mg; 500mg</td>
<td>Dossiers will be submitted in 2017.09</td>
</tr>
<tr>
<td>Iron Sucrose Injection</td>
<td>100mg</td>
<td>Passed GMP audits by several South America Countries</td>
</tr>
<tr>
<td>Ibandronate Sodium Injection</td>
<td>1ml/ampoule</td>
<td>Passed GMP audits by several South America Countries</td>
</tr>
</tbody>
</table>

Products under the patent are only for R&D use.